Impact of androgen deprivation therapy on mood, cognition, and risk for AD

androgen deprivation therapy and cardiovascular risk

Androgen Deprivation Therapy and Cardiovascular Risk

PURPOSE The potential association between androgen deprivation therapy (ADT) and cardiovascular mortality (CVM) remains controversial. This study assessed mortality outcomes in a large national registry to further elucidate the association between treatment selection and cause of mortality. PATIENTS AND METHODS A total of 7,248 men in the CaPSURE registry were analyzed. Treatment was categori...

Impact of androgen deprivation therapy on sexual function: a response.

Dear Editors, We appreciate the growing interest in sexual health for cancer patients and survivors. Mazzola and Mulhall’s recent paper, however, creates the impression that rewarding sex is not possible for prostate cancer patients on androgen deprivation therapy (ADT). This impression, we believe, is not scientifically justified, and may be a disservice to prostate cancer patients and their p...

Impact of androgen deprivation therapy on sexual function.

Many patients with prostate cancer for whom androgen deprivation therapy (ADT) is indicated are young and desire to remain sexually active. In such patients, the side effects of androgen therapy on sexual function can be a source of serious reduction in overall quality of life. Providing the appropriate treatment options in this patient population is therefore essential. Nevertheless, treating ...

Cardiovascular risk associated with androgen deprivation therapy.

Prostate cancer is the second leading cause of cancer-related death among men in the United States.[1] Androgen deprivation therapy (ADT) is a common treatment for prostate cancer. ADT includes gonadotropin-releasing hormone (GnRH) agonists (leuprolide, goserelin, triptorelin), bilateral orchiectomy, and anti-androgen receptor blockers such as flutamide and bicalutamide. Several studies have no...